Abstract
Enrollment into cancer prevention and early detection clinical trials represents a unique challenge compared with a diagnostic or treatment trial because it involves subjects without a diagnosis of cancer. This paper examines some of the barriers to participation in prevention and early detection trials and provides detailed information about two ongoing prevention and two ongoing early detection clinical trials open to enrollment as well as brief summaries of seven additional trials now open to enrollment.
MeSH terms
-
Anticarcinogenic Agents / adverse effects
-
Anticarcinogenic Agents / therapeutic use
-
Antioxidants / therapeutic use
-
Breast Neoplasms / diagnosis
-
Breast Neoplasms / prevention & control
-
Clinical Trials as Topic*
-
Female
-
Humans
-
Lung Neoplasms / diagnosis*
-
Male
-
Neoplasms / diagnosis*
-
Neoplasms / prevention & control*
-
Patient Selection
-
Primary Health Care*
-
Prostatic Neoplasms / prevention & control
-
Raloxifene Hydrochloride / adverse effects
-
Raloxifene Hydrochloride / therapeutic use
-
Selenium / therapeutic use
-
Tamoxifen / adverse effects
-
Tamoxifen / therapeutic use
-
Vitamin E / therapeutic use
Substances
-
Anticarcinogenic Agents
-
Antioxidants
-
Tamoxifen
-
Vitamin E
-
Raloxifene Hydrochloride
-
Selenium